Source: https://www.arnoldporter.com/en/people/h/hughes-rhiannon
Timestamp: 2019-04-24 01:53:50+00:00

Document:
Rhiannon Hughes has considerable experience of large multiparty pharmaceutical product liability matters, including the Third Generation Oral Contraceptives Litigation, the MMR Litigation, the Fetal Anti-Convulsant litigation, and the Rosiglitazone Group Litigation - all of which were successfully defended.
Rhiannon has also assisted in several high profile competition cases, both in the EU and UK, in which she manages the disclosure obligations of clients. She has experience of public and administrative law cases, including acting for a number of pharmaceutical clients against government regulatory bodies and manufacturers of generic medicines, concerning the regulation and licensing of innovative medicinal products.
Rhiannon has a joint honours degree in Spanish and Italian and is also a fluent Welsh speaker, with a working knowledge of French.
The Queen, on the application of Pfizer Ltd v. The Secretary of State for Health Case: C/2002/0860 (CA).
The Queen, on the application of Merck Sharpe & Dohme Ltd v. Licensing Authority Case: CO/4102/2004.
Case C-106/01 – The Queen, on the application of Novartis v. The Licensing Authority.
Case C-36/03 – The Queen, on the application of Approved Prescription Services Ltd v. Licensing Authority.
Case C-452/06 – The Queen, on the application of Synthon BV v. Licensing Authority ex parte Smithkline Beecham.
The Oral Contraceptive Group Litigation – XYZ & Others v. Schering Health Care Limited & Others (2002) EWHC 1420 (QB) – product liability group action arising from increased risk of thrombotic events allegedly associated with third generation combined oral contraceptives.
Sayers and others v. Sanofi Pasteur MSD Limited and others (MMR group litigation).
Fetal Anticonvulsant Litigation – group litigation brought on behalf of children of mothers with epilepsy who alleged that they had sustained congenital abnormalities as a result of exposure to anti-epileptic medication during pregnancy: 2011.
The Roziglitazone Litigation – group litigation brought by Type II diabetics alleging side effects as a result of ingestion of anti-diabetic treatments: 2014.

References: v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v.